What two years of calorie restriction did to healthy humans in the CALERIE trial

The best human test of whether eating less slows ageing is the CALERIE trial, and its most useful lesson is double-edged: two years of sustained calorie restriction in healthy, non-obese adults measurably improved cardiometabolic risk factors and modestly slowed one validated marker of biological ageing — but the volunteers came nowhere near the 25% restriction they were asked to maintain [s1][s2][s3]. That combination, a real biological effect from an intake cut roughly half the prescribed size, is what separates the evidence from the internet folklore around fasting and "starving off" old age.

CALERIE was a phase 2, multicentre randomised controlled trial in three US centres, enrolling young and middle-aged (21 to 50 years), healthy adults who were not obese, with a body-mass index of 22.0 to 27.9 [s1]. Participants were randomised 2:1 to a diet targeting a 25% cut in calories or to eating freely, and followed for two years — a scale and duration no other calorie-restriction study in humans has matched [s1].

What people actually managed

The adherence numbers matter because they reframe every downstream result. Of 218 participants who started, 143 (66%) were assigned to restriction and 75 (34%) to the control diet [s1]. The restriction group achieved a mean calorie reduction of 11.9% (SE 0.7) — from about 2,467 to 2,170 kcal a day — against 0.8% in the control group, and sustained a mean weight loss of 7.5 kg versus a 0.1 kg gain in controls, of which 71% was fat mass [s1]. The trial's earlier feasibility report put the achieved restriction similarly at 11.7% (SE 0.7) with 10.4% weight loss [s3]. Either way, a group asked to cut a quarter of its calories for two years managed roughly half of that — a finding about human behaviour as much as physiology, and a caution against extrapolating from rodent studies that impose restriction the animals cannot refuse.

Adherence held up better than the restriction depth: 82% of the restriction group and 95% of the control group completed the two-year protocol [s3]. The feasibility report also captured the body's expected pushback. Resting metabolic rate, adjusted for weight change, fell significantly more in the restriction group at 12 months (p = .04) but the difference had faded by 24 months, while plasma triiodothyronine (T3), a thyroid hormone that tracks energy status, was lower in the restriction group at both 12 and 24 months [s3]. Those are the fingerprints of metabolic adaptation — the reason sustained restriction gets harder over time and its measurable effects can plateau.

The cardiometabolic effect was real

Even at that partial dose, the metabolic payoff was consistent. Two years of restriction produced persistent, significant reductions from baseline in essentially all the conventional cardiometabolic risk factors measured — systolic, diastolic and mean blood pressure, LDL and other plasma lipids, high-sensitivity C-reactive protein, a metabolic-syndrome score, and glucose-homeostasis measures including fasting insulin [s1]. Notably, these were lean-to-normal-weight people starting within the normal range, so the improvements were not simply the well-known benefits of treating obesity; the authors framed them as a potential cardiovascular advantage of moderate restriction in healthy adults [s1].

The ageing signal was modest and specific

The claim that restriction slows ageing itself rests on a narrower, softer result. A post-hoc analysis applied DNA-methylation "clocks" to blood from 220 participants in the trial and found that restriction slowed the pace of ageing as measured by one algorithm, DunedinPACE, but did not significantly change biological-age estimates from other clocks including PhenoAge and GrimAge [s2]. The treatment effect sizes were small [s2]. That is an honest split result: one measure of the rate of ageing moved, two measures of accumulated ageing did not, and none of it tracked disease or death. The authors were careful to say a conclusive test of whether restriction extends healthy life will need trials long enough to record real endpoints, not just methylation readouts [s2].

What CALERIE does and does not license

Taken together, the trial supports a measured statement and refutes an oversold one. Sustained, moderate calorie restriction is feasible in healthy adults, improves cardiometabolic risk markers and nudges one ageing biomarker — a genuinely supportive result for the geroscience hypothesis [s1][s2]. It does not show that restriction lengthens human life or prevents any specific disease, and it quietly documents that even motivated volunteers in a supported trial cannot sustain the deep restriction that anti-ageing enthusiasts prescribe [s1][s3].

For related interventions, the site has covered the CALERIE strength-preservation sub-study, the periodic alternative of a fasting-mimicking diet, the wider intermittent-fasting evidence, and why metformin's geroprotector case rests on null trials.